Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective

References

• Nair KPS, Marsden J. The management of spasticity in adults. BMJ. 2014;349:g4737.
   PubMed Web of Science ®Google Scholar
• Sampson FC, Hayward A, Evans G, et al. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg. 2002;96:1052–1057.
   PubMed Web of Science ®Google Scholar
• Vivancos-matellano F, Pascual-pascual SI, Nardi-vilardaga J, et al. [Guide to the comprehensive treatment of spasticity]. Rev Neurol. 2007;45:365–375.
   PubMed Web of Science ®Google Scholar
• Bavikatte G, Gaber T. Approach to spasticity in general practice. Br J Med Pract. 2009;2:29–34.
   Google Scholar
• Ward AB. A summary of spasticity management–a treatment algorithm. Eur J Neurol. 2002;9:48–52.
   PubMed Web of Science ®Google Scholar
• Hsieh JC, Penn RD. Intrathecal baclofen in the treatment of adult spasticity. Neurosurg Focus. 2006;21:e5.
   PubMedGoogle Scholar
• McIntyre A, Mays R, Mehta S, et al. Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systematic review. J Spinal Cord Med. 2014;37:11–18.
   PubMed Web of Science ®Google Scholar
• Medical Advisory Secretariat. Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ont Health Technol Assess Ser. 2005;5:1–93.
   Google Scholar
• Vidal J, Fenollosa P, Martin E, et al. Safety and efficacy of intrathecal baclofen infusion by implantable pump for the treatment of severe spinal spasticity: a Spanish multicenter study. Neuromodulation. 2000;3:175–182.
   PubMed Web of Science ®Google Scholar
• Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13:301–306.
   PubMed Web of Science ®Google Scholar
• Zahavi A, Geertzen JHB, Middel B, et al. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry. 2004;75:1553–1557.
   PubMed Web of Science ®Google Scholar
• Saulino M, Guillemette S, Leier J, et al. Medical cost impact of intrathecal baclofen therapy for severe spasticity. Neuromodulation. 2015;18:141–149.
   PubMed Web of Science ®Google Scholar
• Hoving MA, Evers SMAA, Ament AJHA, et al. Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness analysis. Dev Med Child Neurol. 2008;50:450–455.
   PubMed Web of Science ®Google Scholar
• de Lissovoy G, Matza LS, Green H, et al. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol. 2007;22:49–59.
   PubMed Web of Science ®Google Scholar
• Bensmail D, Ward AB, Wissel J, et al. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity. Neurorehabil Neural Repair. 2009;23:546–552.
   PubMed Web of Science ®Google Scholar
• Hattori N, Hirayama T, Katayama Y. Cost-effectiveness analysis of intrathecal baclofen therapy in Japan. Neurol Med Chir (Tokyo). 2012;52:482–487.
   PubMed Web of Science ®Google Scholar
• Mathur SN, Chu SK, McCormick Z, et al. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. PM R. 2014;6:506–513.e1.
   PubMedGoogle Scholar
• Natale M, Mirone G, Rotondo M, et al. Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future prospectives. Clin Neurol Neurosurg. 2012;114:321–325.
   PubMed Web of Science ®Google Scholar
• Draulans N, Vermeersch K, Degraeuwe B, et al. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil. 2013;27:1137–1143.
   PubMed Web of Science ®Google Scholar
• Borrini L, Bensmail D, Thiebaut JB, et al. Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults. Arch Phys Med Rehabil. 2014;95:1032–1038.
   PubMed Web of Science ®Google Scholar
• Heetla HW, Staal MJ, Kliphuis C, et al. The incidence and management of tolerance in intrathecal baclofen therapy. Spinal Cord. 2009;47:751–756.
   PubMed Web of Science ®Google Scholar
• Flückiger B, Knecht H, Grossmann S, et al. Device-related complications of long-term intrathecal drug therapy via implanted pumps. Spinal Cord. 2008;46:639–643.
   PubMed Web of Science ®Google Scholar
• Vidal J, Gregori P, Guevara D, et al. Efficacy of intrathecal morphine in the treatment of baclofen tolerance in a patient on intrathecal baclofen therapy (ITB). Spinal Cord. 2004;42:50–51.
   PubMed Web of Science ®Google Scholar
• Ordia JI, Fischer E, Adamski E, et al. Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation. 2002;5:16–24.
   PubMed Web of Science ®Google Scholar
• Spanish National Statistics Institute. INEbase [ cited 2015 Mar 15]. Available from: http://www.ine.es
   Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. A proposed guideline for economic evaluation of health technologies. Gac Sanit. 2010;24:154–170.
   PubMed Web of Science ®Google Scholar
• Delhaas EM, Beersen N, Redekop WK, et al. Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation. 2008;11:227–236.
   PubMed Web of Science ®Google Scholar
• Medtronic Inc. Medtronic product performance report 2014 [ cited 2015 Nov 20]. Available from: http://professional.medtronic.com/ppr/intrathecal-drug-delivery-systems/index.htm
   Google Scholar
• Saval A, Chiodo AE. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin. J Spinal Cord Med. 2010;33:16–21.
   PubMed Web of Science ®Google Scholar
• De Cock E, Miravitlles M, González-Juanatey JR, et al. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. PharmacoEconomics Spanish Res Artic. 2007;4:97–107.
   Google Scholar
• Rodriguez JM, Paz S, Lizan L, et al. The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990–2009 literature. Value Health. 2011;14:458–464.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16:334–343.
   PubMedGoogle Scholar
• Guillaume D, Van Havenbergh A, Vloeberghs M, et al. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil. 2005;86:2165–2171.
   PubMed Web of Science ®Google Scholar
• Staal C, Arends A, Ho S. A self-report of quality of life of patients receiving intrathecal baclofen therapy. Rehabil Nurs. 2003;28:159–163.
   PubMedGoogle Scholar
• Vender JR, Hughes M, Hughes BD, et al. Intrathecal baclofen therapy and multiple sclerosis: outcomes and patient satisfaction. Neurosurg Focus. 2006;21:e6.
   PubMedGoogle Scholar
• Gunnarsson S, Samuelsson K. Patient experiences with intrathecal baclofen as a treatment for spasticity – a pilot study. Disabi Rehabil. 2015;37:834–841.
   PubMed Web of Science ®Google Scholar
• Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006;253:563–569.
   PubMed Web of Science ®Google Scholar
• Dones I, Marchetti M, Sinisi M, et al. Cautious use of intrathecal baclofen in severely spastic walking patients. Mov Disord. 2002;17:S337–S337.
   Google Scholar
• Schiess MC, Oh IJ, Stimming EF, et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation. 2011;14:38–45.
   PubMed Web of Science ®Google Scholar
• Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the “5E” study. Expert Rev Pharmacoecon Outcomes Res. 2011;11:205–213.
   PubMed Web of Science ®Google Scholar
• Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci. 2013;123:850–858.
   PubMed Web of Science ®Google Scholar
• Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost–effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012;12:439–441.
   PubMed Web of Science ®Google Scholar
• Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand. 2014;129:13–20.
   PubMed Web of Science ®Google Scholar
• Slof J, Serrano D, Álvarez López-Dóriga M, et al. Clinical outcomes and health care resource utilization in a 1-year observational study of patients with non-focal disabling spasticity who are resistant or intolerant to oral therapy treated with intrathecal baclofen therapy at the Institut Guttmann (Spain). Epice study. Value Health. 2014;17:A396.
   Google Scholar
• General Council of Spanish Pharmacists. Official medicines catalog [ cited 2014 Feb 27]. Available from: https://botplusweb.portalfarma.com/
   Google Scholar